FDA’s AI Risk-Based Guidance Shifts Validation Burden to Sponsors - The Clinical Trial Vanguard

This regulatory shift enhances AI governance in clinical trials by placing validation responsibilities on sponsors, potentially improving safety.

Auto-scored: It is a minor regulatory framing that contributes substantive governance without indicating direct risk escalation.